Obgemsa (Vibegron)

What Is Obgemsa and What Is It Used For?

Obgemsa contains the active substance vibegron, which belongs to a class of medications known as beta-3 adrenoceptor agonists. These medications work by activating specific receptors (beta-3 adrenoceptors) located on the smooth muscle of the urinary bladder. When activated, these receptors cause the detrusor muscle to relax during the filling phase of the bladder, effectively increasing bladder capacity and reducing involuntary contractions that cause the symptoms of overactive bladder (OAB).

Overactive bladder is a common condition affecting millions of adults worldwide, with prevalence increasing with age. Studies indicate that approximately 12-17% of the adult population experiences OAB symptoms, though many cases go unreported due to the personal nature of the condition. The condition significantly impacts quality of life, affecting sleep patterns, work productivity, social interactions, and mental well-being.

Obgemsa is specifically indicated for the treatment of the following overactive bladder symptoms in adults:

• Urinary urgency: A sudden, compelling need to urinate that is difficult to defer. This is the hallmark symptom of OAB and can occur at any time, often without warning.
• Increased urinary frequency: The need to urinate more often than usual, typically defined as more than eight times during waking hours. This can significantly disrupt daily activities and routines.
• Urge urinary incontinence: The involuntary leakage of urine associated with a sudden, strong urge to urinate. Not all patients with OAB experience incontinence, but it is a common and distressing symptom for those who do.

The mechanism of action of vibegron is distinct from that of anticholinergic medications (such as oxybutynin, solifenacin, and tolterodine), which have traditionally been the first-line pharmacological treatment for OAB. While anticholinergics block muscarinic receptors to reduce bladder contractions, vibegron works by directly relaxing the detrusor muscle through beta-3 adrenoceptor stimulation. This difference in mechanism is clinically important because it means that vibegron does not produce the typical anticholinergic side effects such as dry mouth, constipation, blurred vision, and cognitive impairment, which are common reasons patients discontinue anticholinergic therapy.

Clinical trials have demonstrated that vibegron significantly reduces the number of daily urgency episodes, voiding frequency, and incontinence episodes compared to placebo. The EMPOWUR trial, a pivotal phase 3 randomized controlled trial, showed that vibegron 75 mg once daily produced statistically significant improvements in all primary and secondary endpoints compared to placebo, with improvements observed as early as two weeks after initiation of treatment.

What Should You Know Before Taking Obgemsa?

Contraindications

Obgemsa must not be used if you are allergic (hypersensitive) to vibegron or any of the other ingredients in the tablet. The inactive ingredients include mannitol, microcrystalline cellulose, croscarmellose sodium, hydroxypropylcellulose, magnesium stearate, and the film-coating components. If you have previously experienced an allergic reaction to any of these substances, inform your healthcare provider before starting treatment.

Warnings and Precautions

Before starting treatment with Obgemsa, discuss the following important points with your healthcare provider:

• Bladder outlet obstruction: If you have difficulty emptying your bladder (urinary retention), a weak urine stream, or are currently taking other medications for overactive bladder such as anticholinergics (e.g., oxybutynin, diphenhydramine, or solifenacin), you may be at increased risk of urinary retention. Vibegron relaxes the bladder muscle, which in patients with pre-existing outflow obstruction may further impair the ability to void. Your doctor should carefully evaluate the benefit-risk ratio before prescribing Obgemsa in these circumstances.
• Severe hepatic impairment: Obgemsa should not be used in patients with severe liver problems, as the drug's metabolism and clearance may be significantly altered, potentially leading to increased drug exposure and a higher risk of adverse effects.
• End-stage renal disease (ESRD): Obgemsa is not recommended for patients with end-stage kidney disease, as there is insufficient data on the safety and efficacy of vibegron in this population. The kidneys play a role in the elimination of vibegron and its metabolites, and severely impaired renal function may result in unpredictable drug levels.

Children and Adolescents

Obgemsa should not be given to children and adolescents under 18 years of age. The safety and efficacy of vibegron have not been established in this age group. The pharmacokinetics of vibegron in pediatric populations have not been studied, and the appropriate dosage for children is unknown. If a child or adolescent has symptoms of overactive bladder, consult a pediatric urologist for appropriate evaluation and treatment options.

Pregnancy and Breastfeeding

Pregnancy: Obgemsa should not be taken during pregnancy. There are no adequate and well-controlled clinical studies of vibegron in pregnant women. Animal reproduction studies are insufficient to fully characterize the potential risks. Because the effects on the developing fetus are unknown, the potential risk to the unborn child cannot be excluded. If you discover that you are pregnant while taking Obgemsa, discontinue the medication and contact your healthcare provider.

Breastfeeding: It is likely that vibegron passes into breast milk, but the risks to the nursing infant are unknown. Because of the potential for adverse effects in the breastfed infant, you should not breastfeed while taking Obgemsa. Discuss with your healthcare provider whether the benefits of breastfeeding outweigh the risks of either discontinuing the medication or discontinuing breastfeeding.

Fertility: There are no clinical data on the effects of vibegron on human fertility. If you are concerned about your fertility or are trying to conceive, discuss this with your healthcare provider.

Driving and Operating Machinery

Obgemsa has no or negligible effect on the ability to drive and operate machinery. Clinical studies have not shown any significant impairment of cognitive function, reaction time, or psychomotor performance with vibegron treatment. Unlike some anticholinergic OAB medications, which can cause drowsiness, blurred vision, or cognitive effects that impair driving ability, Obgemsa does not affect the central nervous system in a clinically significant manner.

Special Information About Excipients

Lactose: Obgemsa film-coating contains lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The amount of lactose in the film-coating is small, but patients with severe lactose intolerance should be aware of this ingredient.

Sodium: This medicine contains less than 1 mmol (23 mg) sodium per tablet, i.e., it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.

How Does Obgemsa Interact with Other Drugs?

Drug interactions are an important consideration when starting any new medication. Vibegron, the active ingredient in Obgemsa, is a substrate and inhibitor of certain drug transporters, which can affect the absorption and blood levels of co-administered medications. Understanding these interactions is essential for safe and effective use of Obgemsa.

Always tell your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take in the future. This includes prescription medications, over-the-counter products, vitamins, and herbal supplements. Some interactions may require dose adjustments or closer monitoring by your healthcare provider.

Major Interactions

Other Considerations

While vibegron has a relatively limited interaction profile compared to many other medications, its inhibition of P-glycoprotein (P-gp) transporters is the primary mechanism responsible for the clinically significant interactions listed above. P-gp is an efflux transporter found in the intestine, liver, kidneys, and blood-brain barrier. When inhibited by vibegron, drugs that are P-gp substrates may have increased oral bioavailability and reduced elimination, leading to higher blood levels.

There are no known significant interactions between vibegron and common over-the-counter pain relievers (paracetamol/acetaminophen, ibuprofen), proton pump inhibitors, or most antibiotics. However, it is always good practice to inform your healthcare provider about all substances you use, including supplements and herbal products, as new interactions may be identified over time as post-marketing data accumulate.

Patients already taking anticholinergic medications for overactive bladder who are switching to vibegron should discuss the transition plan with their doctor. Combining vibegron with anticholinergics may increase the risk of urinary retention, particularly in patients with bladder outlet obstruction. Your physician will advise you on the appropriate timing for stopping one medication and starting another.

What Is the Correct Dosage of Obgemsa?

Always take Obgemsa exactly as your doctor has told you. If you are unsure about anything, ask your doctor or pharmacist. The standard dosing regimen for Obgemsa is straightforward, which helps promote medication adherence and consistent symptom control.

Adults

If you have difficulty swallowing tablets, Obgemsa can be crushed and mixed with approximately one tablespoon (about 15 mL) of soft food, such as applesauce or yogurt. Eat the mixture immediately after preparation, and follow with a glass of water. Do not store the crushed tablet mixture for later use, as this may affect the drug's stability and bioavailability.

No dose adjustment is required for patients with mild-to-moderate hepatic impairment or mild-to-moderate renal impairment. However, as noted earlier, Obgemsa should not be used in patients with severe hepatic impairment or end-stage renal disease.

Elderly Patients

Clinical studies included a significant proportion of patients aged 65 years and older, and no overall differences in safety or efficacy were observed between these patients and younger adults. However, elderly patients are more likely to have other medical conditions and take multiple medications, so the potential for drug interactions should always be considered. Regular follow-up appointments with your healthcare provider are recommended.

Children and Adolescents

Missed Dose

If you miss a dose of Obgemsa, simply take your next dose at the usual time the following day. Do not take a double dose to make up for a forgotten tablet, as this will not improve your symptoms and may increase the risk of side effects. If you miss several doses in a row, tell your doctor and follow the advice given. The steady-state levels of vibegron take approximately seven days to establish, so occasional missed doses may result in temporary reduction of symptom relief.

Overdose

If you have taken more Obgemsa tablets than prescribed, contact your doctor, pharmacist, or emergency department immediately for advice. This applies both if you have taken too many tablets yourself and if someone else has accidentally taken your medication.

Symptoms of overdose may include problems with the digestive system (nausea, vomiting, diarrhea), headache, and respiratory difficulties. There is no specific antidote for vibegron overdose. Treatment is supportive and symptomatic. In the event of overdose, general measures to remove unabsorbed drug from the gastrointestinal tract may be considered if the patient presents shortly after ingestion.

Stopping Treatment

Do not stop taking Obgemsa early if you do not see an immediate effect. Your bladder may need some time to adjust to the medication, and the full benefit may not be apparent for several weeks. In clinical trials, significant improvements were observed as early as two weeks, but optimal results were typically achieved after 12 weeks of continuous treatment.

Do not stop taking Obgemsa when your symptoms improve, as the symptoms of overactive bladder may return if treatment is discontinued. If you wish to stop treatment, talk to your doctor first. Your healthcare provider can help you develop a plan that may include gradual dose reduction or alternative therapies to manage your symptoms.

What Are the Side Effects of Obgemsa?

Like all medicines, Obgemsa can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and tend to resolve on their own as your body adjusts to the medication. Clinical trials have shown that the overall rate of side effects with vibegron is similar to placebo for many categories, reflecting its favorable tolerability profile.

It is important to be aware of the potential side effects so you can recognize them early and seek appropriate medical attention when necessary. The following side effects have been reported in clinical trials and post-marketing experience:

Compared to anticholinergic OAB medications, vibegron has a notably lower incidence of dry mouth, which is one of the most common reasons patients discontinue anticholinergic therapy. In the pivotal EMPOWUR trial, the incidence of dry mouth with vibegron was similar to placebo (2.8% vs. 2.2%), compared to substantially higher rates seen with anticholinergics such as tolterodine (reported at approximately 18-37% in clinical trials).

The cardiovascular safety profile of vibegron is an important consideration, particularly in elderly patients. Unlike mirabegron (another beta-3 agonist), vibegron has shown minimal effects on heart rate and blood pressure in clinical trials. The EMPOWUR trial demonstrated no clinically meaningful increases in heart rate or blood pressure compared to placebo, supporting its cardiovascular safety.

If you experience any side effects not listed here, or if any side effects become severe, please contact your healthcare provider. Reporting side effects helps build the post-marketing safety profile of the medication and contributes to ongoing safety monitoring. Suspected adverse reactions can be reported through your national pharmacovigilance reporting system.

How Should You Store Obgemsa?

Proper storage of medications is essential to maintain their effectiveness and safety. The following guidelines should be observed for Obgemsa:

• Keep out of reach: Store this medicine out of the sight and reach of children. Use the child-resistant cap provided on the plastic bottle.
• Expiry date: Do not use Obgemsa after the expiry date which is printed on the carton and bottle after "EXP." The expiry date refers to the last day of that month.
• Storage conditions: No special storage conditions are required. Store at room temperature and protect from excessive heat and moisture.
• Disposal: Do not dispose of medicines in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment.

Obgemsa is supplied in white, square or round plastic bottles with child-resistant plastic closures. The tablets are available in pack sizes of 7, 30, or 90 film-coated tablets. Not all pack sizes may be marketed in all countries. Keep the bottle tightly closed when not in use to protect the tablets from moisture.

What Does Obgemsa Contain?

Understanding the full composition of a medication is important, particularly for patients with allergies or sensitivities to specific ingredients. Below is the complete list of ingredients in Obgemsa:

Active Ingredient

Each film-coated tablet contains 75 mg of vibegron.

Inactive Ingredients (Excipients)

Tablet core: mannitol, microcrystalline cellulose, croscarmellose sodium, hydroxypropylcellulose, and magnesium stearate.

Film-coating: indigo carmine aluminum lake (E132), hypromellose (E464), yellow iron oxide (E172), lactose, titanium dioxide (E171), and triacetin.

Tablet Appearance

Obgemsa tablets are light green, oval-shaped film-coated tablets engraved with "V75" on one side and plain on the other side. The tablet dimensions are approximately 9 mm (length) x 4 mm (width) x 3 mm (height). The tablets are supplied in white, square or round plastic bottles with child-resistant plastic closures in pack sizes of 7, 30, or 90 tablets.

The marketing authorization holder is Pierre Fabre Medicament, Les Cauquillous, 81500 Lavaur, France. The manufacturer is Patheon France, 40 boulevard de Champaret, 38300 Bourgoin Jallieu, France.